Ghaleb, A., Hamed, E., Boghdady, A., Hassanin, H. (2018). Ischemic Heart Disease in Patients with Diabetes Mellitus. test, 22(1), 281-290. doi: 10.21608/smj.2018.41796
Alaa Ahmed Ghaleb; Elham Omar Hamed; Ahmed Mohamed Boghdady; Hassan Ahmed Hassanin. "Ischemic Heart Disease in Patients with Diabetes Mellitus". test, 22, 1, 2018, 281-290. doi: 10.21608/smj.2018.41796
Ghaleb, A., Hamed, E., Boghdady, A., Hassanin, H. (2018). 'Ischemic Heart Disease in Patients with Diabetes Mellitus', test, 22(1), pp. 281-290. doi: 10.21608/smj.2018.41796
Ghaleb, A., Hamed, E., Boghdady, A., Hassanin, H. Ischemic Heart Disease in Patients with Diabetes Mellitus. test, 2018; 22(1): 281-290. doi: 10.21608/smj.2018.41796

Ischemic Heart Disease in Patients with Diabetes Mellitus

Sohag Medical Journal
Article 43, Volume 22, Issue 1, January 2018, Pages 281-290    PDF (88.4 K)
Document Type: Original Article
DOI: 10.21608/smj.2018.41796
Authors
Alaa Ahmed Ghaleb1; Elham Omar Hamed2; Ahmed Mohamed Boghdady3; Hassan Ahmed Hassanin1
1Department of Internal Medicine, Faculty of Medicine, Sohag University.
2Department of Clinical andChemical pathology, Sohag Faculty of Medicine, Sohag University.
3Department of Internal Medicine, Faculty of Medicine, Sohag University.
References
  1. World Health Organization. World Health Statistics. Department of Measurement & Health Information Systems of the Information, Evidence and Research Cluster. Geneva: WHO Press; 2008. p. 29-31.
  2. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321 : 412-9.
  3. American Diabetes A. Standards of Medical Care in Diabetes--2008. Diabetes Care 2008; 31 (Suppl 1): S12-54.
  4. American Diabetic Association: Standards of medical care in diabetes- 2009. Diabetes Care 2009;32(suppl 1):S13-S61.
  5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 : 71-86.
  6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 : 1849-60.
  7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 : 1267-78.
  8. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardio 2002; 90 : 625-8.
  9. Buse JB, Rosenstock J. Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. Endocrinol Metab Clin North Am 2005; 34 : 221-35.
  10. Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clin Exp Pharmacol Physiol 2008; 35 : 434-7.
  11. Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, Froguel P, et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet 2008; 40 : 716-8.
  12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 : 685-96.
  13. Collins R, Armitage J, Parish S, Sleigh P, Peto R; MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361 : 2005-16.
  14. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 : 827-38.
  15. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005; 118 : 939-47.
  16. Diaz VA, Mainous AG, 3rd, Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007; 24 : 1199-204.
  17. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360 : 129-39.
  18. Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and therapy. Coronary Artery Disease in Asian Indians (CADI) Study. Clin Cardiol 1993; 18 : 131-5.
  19. Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006; 19 : 1241-8.
  20. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393, 2003.
  21. Gaziano TA, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular Disease. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al, editors. Disease control priorities in developing countries, 2nd ed. New York: Oxford University Press; 2006. p. 645-62.
  22. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 : 2545-59.
  23. Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ 2004; 328 : 807-10.
  24. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, et al. Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol 2007; 99 (Suppl 1): S56-S67.
  25. Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol 2006; 22 : 193-7.
  26. Gupta R, Gupta VP, Sarna M, Prakash H, Rastogi S, Gupta KD. Serial epidemiological surveys in an urban Indian population demonstrate increasing coronary risk factors among the lower socioeconomic strata. J Assoc Physicians India 2003; 51 : 470-7
  27. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94 : 16-26.
  28. Gupta R, Kumar P. Global diabetes landscape - Type 2 diabetes mellitus in south Asia: Epidemiology, risk factors, and control. Insulin 2008; 3 : 78-94.
  29. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A): 6S-11S.
  30. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351 : 1755-62.
  31. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 : 1577-89.
  32. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 2005; 112 : 924-34.
  33. International Diabetes Federation (IDF). Diabetes atlas 4th ed. 2009. Available at: www.diabetesatlas.org. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors 
Statistics
Article View: 120
PDF Download: 258